<DOC>
	<DOCNO>NCT00512486</DOCNO>
	<brief_summary>The primary objective study investigate safety administration drug increase dos male female adult subject mild asthma .</brief_summary>
	<brief_title>A Sequential Dose-Escalation Study Subjects With Mild Asthma</brief_title>
	<detailed_description>The primary objective study investigate safety administration BIW-8405/MEDI-563 increase dos male female adult subject mild asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Male female subject age 18 45 year good general health asthma consistent definition mild ( intermittent persistent ) asthma 2002 Expert Panel report NAEPP : Night time symptom weekly day time symptom &lt; 1 per day ; lung function , FEV1 PEF ≥ 80 % predict value PEF variability ≤ 30 % . Note : Principal Investigator must determine subject 's asthma consistent definition e.g. , require Investigator obtain historical PEF value calculate variability . 2 . Subjects PC20 methacholine ≤ 8 mg/mL Visit 1 ( require subject Cohorts 57 ) document within 6 month prior Visit 1 ( subject Cohorts 14 ) .3 . Subjects provide write informed consent . Written informed consent must obtain prior perform study related procedure . 4 . Subjects consider Principal Investigator otherwise healthy , judged absence clinically significant disease clinically significant abnormal laboratory value would confound interpretation study . 5 . Women must post menopausal , surgically sterile willing use birth control duration study . Birth control may include double barrier method ( e.g. , condom spermicide , hormonal contraceptive ( provide use regularly least 3 menstrual cycle ) IUD ( provide remain situ least three menstrual cycle ) . 1 . All asthmatic subject receive topical steroid ( except nonprescription topical steroid dermatologic condition ) within 6 month prior Visit 1 exclude . 2 . Any subject requiring prescription medication , contraceptives β2 agonist ( eg , albuterol ) anticholinergic agent ( eg , ipratropium ) treatment mild asthma study . Subjects take nonprescription medication must willing able refrain use inpatient period study . 3 . Any subject smoke cigarette cigar within one year prior Visit 2 smoke &gt; 5 pack/years . 4 . Any subject documented evidence Hepatitis B virus , HIV hepatitis C virus ( HCV ) infection . 5 . Any subject document Mantoux ( PPD ) positive . 6 . Any subject parasitic infection time past intend travel area parasitic infection endemic . 7 . Any subject condition result increase eosinophil count ( except asthma ) screening . 8 . Any subject Body Mass Index less 15 kg/m2 great 30 kg/m2 Visit 1 . 9 . Any subject documented history disorder immune system ( except asthma ) time . 10 . Any subject clinically relevant abnormality laboratory parameter screen period ( except eosinophilia due asthma ) . 11 . Any subject participate study investigational product within either 30 day 10 half life ( know ) prior Visit 2 , whichever longer . 12 . Any subject history dependence alcohol drug abuse positive drug screen Visit 1 . 13 . Any subject know sensitivity constituent BIW8405/MEDI563 IL5 receptor antagonist . 14 . Any subject history cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological disorder capable alter metabolism elimination drug constitute risk factor take study medication . 15 . Any subject clinically significant relevant deviation normal physical examination , electrocardiography , clinical laboratory test , determine Principal Investigator . 16 . Any subject donate blood way loss blood volume great 450 mL within 30 day begin study injection . 17 . Any subject unwilling reside clinic study period unwilling cooperate fully Principal Investigator designee . 18 . Pregnant female exclude study participation . 19 . Any subject plan undergo elective surgery within 4 week Visit 2 ( Day 0 ) end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>